Advertisement

Topics

Profit finally in sight for gene therapy specialist Oxford Bio

05:48 EDT 23 Aug 2017 | Reuters

LONDON (Reuters) - After 20 years of losses, gene therapy specialist Oxford BioMedica is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment.

Original Article: Profit finally in sight for gene therapy specialist Oxford Bio

NEXT ARTICLE

More From BioPortfolio on "Profit finally in sight for gene therapy specialist Oxford Bio"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...